RSS-Feed abonnieren

DOI: 10.1055/s-0045-1809379
Chemotherapy during First Trimester Pregnancy Leading to Fetal Malformation: A Case Report with Review of Literature
Autor*innen
Funding None.
Abstract
Pregnancy coexisting with the diagnosis of malignancy is rare. It poses a major management dilemma to the oncologist where adequate oncology outcomes need to be weighed against the fetal well-being. Use of chemotherapy during pregnancy is determined by the type of malignancy, stage, gestational age, chemotherapy agent, and the risk of placental transfer.
A 33-year-old female patient presented with a gradually progressive breast lump. After adequate workup, the patient was diagnosed with infiltrating duct carcinoma left breast (T3N0M1), with liver metastases and triple-negative breast cancer. Subsequently, the patient received detailed counseling about treatment, prognosis, and contraceptive use to avoid conception and was started on palliative chemotherapy with doxorubicin, cyclophosphamide, and docetaxel. Radiology was performed for response assessment after eight cycles of chemotherapy. It demonstrated an accidental pregnancy of 22 weeks and 4 days gestation with major malformations including corpus callosum agenesis with ventriculomegaly, skeletal dysplasia including hypoplastic upper limbs, and absent radius in one arm. The patient underwent medical termination of pregnancy and further oncology treatment as per response and standard treatment guidelines.
Chemotherapy should be strictly avoided for pregnant patients in the first trimester given its teratogenic effects, leading to major fetal malformations. The use of multiple drugs makes it difficult to establish a causal role of a particular chemotherapeutic agent with specific malformation. Adequate anticonception counseling and pregnancy tests should be offered to women diagnosed with cancer who are in the reproductive age group, prior to starting chemotherapy.
Keywords
pregnancy - chemotherapy - fetal malformations - teratogenic - corpus-callosum agenesis - skeletal dysplasia - case reportAuthors' Contributions
The manuscript has been read and approved by the authors and all have contributed to it.
Patient's Consent
Written consent was taken from the patient to share the clinical details and USG images.
Publikationsverlauf
Artikel online veröffentlicht:
30. Mai 2025
© 2025. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution License, permitting unrestricted use, distribution, and reproduction so long as the original work is properly cited. (https://creativecommons.org/licenses/by/4.0/)
Thieme Medical and Scientific Publishers Pvt. Ltd.
A-12, 2nd Floor, Sector 2, Noida-201301 UP, India
-
References
- 1 Melan K, Volumenie JL, Wan-Ajouhu G, Ulric-Gervaise S, Veronique-Baudin J, Joachim C. Pregnancy-associated-cancer in the French West Indies (Martinique): maternal and neonatal outcomes. BMC Pregnancy Childbirth 2017; 17 (01) 334
- 2 Silverstein J, Post AL, Chien AJ. et al. Multidisciplinary management of cancer during pregnancy. JCO Oncol Pract 2020; 16 (09) 545-557
- 3 Gupta N, Takkar N. Fertility preservation in women undergoing treatment for malignancies: a narrative review. Int J Reprod Contracept Obstet Gynecol 2024; 13: 776-783
- 4 Peccatori FA, Azim Jr HA, Orecchia R. et al; ESMO Guidelines Working Group. Cancer, pregnancy and fertility: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2013; 24 (Suppl. 06) vi160-vi170
- 5 Prinja S, Gupta N. Value-based pricing for cancer drugs in India. Cancer Res Stat Treat 2021; 4: 559-560
- 6 van Gerwen M, Maggen C, Cardonick E. et al. International Network on Cancer, Infertility and Pregnancy. association of chemotherapy timing in pregnancy with congenital malformation. JAMA Netw Open 2021; 4 (06) e2113180
- 7 Amant F, Berveiller P, Boere IA. et al. Gynecologic cancers in pregnancy: guidelines based on a third international consensus meeting. Ann Oncol 2019; 30 (10) 1601-1612
- 8 Gupta N, Chugh Y, Prinja S. Bridging the cancer care gap and inequities in radiation treatment in India: a narrative review. Cancer Res Stat Treat 2023; 6: 554-561
- 9 Brewer M, Kueck A, Runowicz CD. Chemotherapy in pregnancy. Clin Obstet Gynecol 2011; 54 (04) 602-618
- 10 Romano A, Mastrangelo S, Attina G, Maurizi P, Ruggiero A. Pregnancy-associated cancer and chemotherapy during pregnancy. Biomed Pharmacol J 2023; •••: 16
- 11 Streffer C, Shore R, Konermann G. et al. Biological effects after prenatal irradiation (embryo and fetus). A report of the International Commission on Radiological Protection. Ann ICRP 2003; 33 (1-2): 5-206
- 12 American College of Radiology. ACR-SPR practice parameter for imaging pregnant or potentially pregnant adolescents and women with ionizing radiation. Resolution 39, 2018. Accessed May 15, 2025 at: https://www.acr. org/-/ media/ ACR/ Files/ Practice- Parameters/ Pregnant- Pts. Pdf
- 13 Accessed May 15, 2025 at: https://www.nccn.org/professionals/physician_gls/pdf/breast.pdf
- 14 Gupta N, Chugh Y, Chauhan AS, Pramesh CS, Prinja S. Cost-effectiveness of post-mastectomy radiotherapy (PMRT) for breast cancer in India: an economic modelling study. Lancet Reg Health Southeast Asia 2022; 4: 100043
- 15 Kal HB, Struikmans H. Radiotherapy during pregnancy: fact and fiction. Lancet Oncol 2005; 6 (05) 328-333
- 16 Pariente G, Leibson T, Carls A, Adams-Webber T, Ito S, Koren G. Pregnancy-associated changes in pharmacokinetics: a systematic review. PLoS Med 2016; 13 (11) e1002160
- 17 Triarico S, Rivetti S, Capozza MA. et al. Transplacental passage and fetal effects of antineoplastic treatment during pregnancy. Cancers (Basel) 2022; 14 (13) 3103
- 18 Cardonick E, Usmani A, Ghaffar S. Perinatal outcomes of a pregnancy complicated by cancer, including neonatal follow-up after in utero exposure to chemotherapy: results of an international registry. Am J Clin Oncol 2010; 33 (03) 221-228
- 19 Gupta N, Pandey A, Dimri K, Prinja S. Epidemiological profile of retinoblastoma in North India: implications for primary care and family physicians. J Family Med Prim Care 2020; 9 (06) 2843-2848
- 20 Garcia V, Miguel JS, Borrasca AL. Doxorubicin in the first trimester of pregnancy. Ann Intern Med 1981; 94 (4 pt 1): 547
- 21 Enns GM, Roeder E, Chan RT, Ali-Khan Catts Z, Cox VA, Golabi M. Apparent cyclophosphamide (cytoxan) embryopathy: a distinct phenotype?. Am J Med Genet 1999; 86 (03) 237-241
- 22 Reynoso EE, Keating A, Baker MA. Acute leukemia occurring 19 years after treatment of acute lymphoblastic leukemia. Cancer 1987; 59 (11) 1963-1965
- 23 Lambertini M, Peccatori FA, Azim Jr HA. Targeted agents for cancer treatment during pregnancy. Cancer Treat Rev 2015; 41 (04) 301-309
- 24 Zagouri F, Sergentanis TN, Chrysikos D, Papadimitriou CA, Dimopoulos MA, Bartsch R. Trastuzumab administration during pregnancy: a systematic review and meta-analysis. Breast Cancer Res Treat 2013; 137 (02) 349-357
- 25 Butani D, Gupta N, Jyani G, Bahuguna P, Kapoor R, Prinja S. Cost-effectiveness of tamoxifen, aromatase inhibitor, and switch therapy (adjuvant endocrine therapy) for breast cancer in hormone receptor positive postmenopausal women in India. Breast Cancer (Dove Med Press) 2021; 13: 625-640
- 26 Pasternak B, Svanström H, Hviid A. Ondansetron in pregnancy and risk of adverse fetal outcomes. N Engl J Med 2013; 368 (09) 814-823
- 27 Cardonick E, Irfan F, Torres N. The use of Neupogen (filgrastim) or Neulasta (pegfilgrastim) during pregnancy when chemotherapy is indicated for maternal cancer treatment. J Cancer Ther 2012; 03: 157-161
- 28 La Nasa M, Gaughan J, Cardonick E. Incidence of neonatal neutropenia and leukopenia after in utero exposure to chemotherapy for maternal cancer. Am J Clin Oncol 2019; 42 (04) 351-354
- 29 Johnson HM, Mitchell KB. Academy of Breastfeeding Medicine. ABM Clinical Protocol #34: breast cancer and breastfeeding. Breastfeed Med 2020; 15 (07) 429-434
- 30 Dixit J, Gupta N, Kataki A. et al. Health-related quality of life and its determinants among cancer patients: evidence from 12,148 patients of Indian database. Health Qual Life Outcomes 2024; 22 (01) 26
